These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 15465629)
1. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Lee JY; Friedman JE; Angel I; Kozak A; Koh JY Neurobiol Aging; 2004; 25(10):1315-21. PubMed ID: 15465629 [TBL] [Abstract][Full Text] [Related]
2. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. van Groen T; Kiliaan AJ; Kadish I Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076 [TBL] [Abstract][Full Text] [Related]
3. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Güntert A; Döbeli H; Bohrmann B Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022 [TBL] [Abstract][Full Text] [Related]
4. A transgenic rat model of Alzheimer's disease with extracellular Abeta deposition. Flood DG; Lin YG; Lang DM; Trusko SP; Hirsch JD; Savage MJ; Scott RW; Howland DS Neurobiol Aging; 2009 Jul; 30(7):1078-90. PubMed ID: 18053619 [TBL] [Abstract][Full Text] [Related]
5. Deposition of lactoferrin in fibrillar-type senile plaques in the brains of transgenic mouse models of Alzheimer's disease. Wang L; Sato H; Zhao S; Tooyama I Neurosci Lett; 2010 Sep; 481(3):164-7. PubMed ID: 20599473 [TBL] [Abstract][Full Text] [Related]
6. Amyloid cored plaques in Tg2576 transgenic mice are characterized by giant plaques, slightly activated microglia, and the lack of paired helical filament-typed, dystrophic neurites. Sasaki A; Shoji M; Harigaya Y; Kawarabayashi T; Ikeda M; Naito M; Matsubara E; Abe K; Nakazato Y Virchows Arch; 2002 Oct; 441(4):358-67. PubMed ID: 12404061 [TBL] [Abstract][Full Text] [Related]
7. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Dedeoglu A; Cormier K; Payton S; Tseitlin KA; Kremsky JN; Lai L; Li X; Moir RD; Tanzi RE; Bush AI; Kowall NW; Rogers JT; Huang X Exp Gerontol; 2004; 39(11-12):1641-9. PubMed ID: 15582280 [TBL] [Abstract][Full Text] [Related]
8. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Garcia-Alloza M; Robbins EM; Zhang-Nunes SX; Purcell SM; Betensky RA; Raju S; Prada C; Greenberg SM; Bacskai BJ; Frosch MP Neurobiol Dis; 2006 Dec; 24(3):516-24. PubMed ID: 17029828 [TBL] [Abstract][Full Text] [Related]
10. Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models. Pereson S; Wils H; Kleinberger G; McGowan E; Vandewoestyne M; Van Broeck B; Joris G; Cuijt I; Deforce D; Hutton M; Van Broeckhoven C; Kumar-Singh S J Pathol; 2009 Oct; 219(2):173-81. PubMed ID: 19557827 [TBL] [Abstract][Full Text] [Related]
11. Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease. He J; Luo H; Yan B; Yu Y; Wang H; Wei Z; Zhang Y; Xu H; Tempier A; Li X; Li XM Neurobiol Aging; 2009 Aug; 30(8):1205-16. PubMed ID: 18079026 [TBL] [Abstract][Full Text] [Related]
12. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Malm TM; Koistinaho M; Pärepalo M; Vatanen T; Ooka A; Karlsson S; Koistinaho J Neurobiol Dis; 2005 Feb; 18(1):134-42. PubMed ID: 15649704 [TBL] [Abstract][Full Text] [Related]
13. Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer's disease. El Tannir El Tayara N; Delatour B; Le Cudennec C; Guégan M; Volk A; Dhenain M Neurobiol Dis; 2006 Apr; 22(1):199-208. PubMed ID: 16337798 [TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Jack CR; Marjanska M; Wengenack TM; Reyes DA; Curran GL; Lin J; Preboske GM; Poduslo JF; Garwood M Neuroscientist; 2007 Feb; 13(1):38-48. PubMed ID: 17229974 [TBL] [Abstract][Full Text] [Related]
15. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400 [TBL] [Abstract][Full Text] [Related]
16. Phosphorylated tau in neuritic plaques of APP(sw)/Tau (vlw) transgenic mice and Alzheimer disease. Pérez M; Morán MA; Ferrer I; Avila J; Gómez-Ramos P Acta Neuropathol; 2008 Oct; 116(4):409-18. PubMed ID: 18679696 [TBL] [Abstract][Full Text] [Related]
17. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau. Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643 [TBL] [Abstract][Full Text] [Related]
18. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease? Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173 [TBL] [Abstract][Full Text] [Related]